Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avexitide - Amylyx Pharmaceuticals

Next Previous
Drug Profile

Avexitide - Amylyx Pharmaceuticals

Alternative Names: Avexitide acetate; Exendin (9-39)amide; Exendin 9; Exendin 9-39 acetate; Exendin-(9-39); Exendin-9,39

Latest Information Update: 22 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Cambridge University Hospitals; Eiger BioPharmaceuticals, Inc.; Stanford University
  • Class Antihypoglycaemics; Peptide fragments
  • Mechanism of Action Glucagon-like peptide-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Congenital hyperinsulinism; Hypoglycaemia

Most Recent Events

  • 15 May 2025 Mayo Clinic plans a phase-II trial for Type 2 diabetes mellitus (In volunteers) in USA (IV, Infusion), (NCT06972407)
  • 12 Mar 2025 Amylyx Pharmaceuticals plans a clinical trial for Kidney disorders in Denmark in May 2025 (IV) (NCT06872060)
  • 04 Mar 2025 Amylyx Pharmaceuticals announces intention to launch avexitide for Post-bariatric hypoglycemia in 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top